| Name | PD-1/PD-L1-IN-9 |
| Description | PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model. |
| In vitro | PD-1/PD-L1-IN-9 (46.9-1500 nM; pretreated for 2 h) enhances the antitumor immunity of PBMCs against MDB-MB 231 cells in a dose-dependent manner, with an EC50 of approximately 100 nM[1]. |
| In vivo | PD-1/PD-L1-IN-9 (40-80 mg/kg; p.o. once a day for 2 weeks) inhibits tumor growth in a dose-dependent manner without causing body weight loss or mortality in mice. PD-1/PD-L1-IN-9 (3 mg/kg; a single i.v.) exhibits a half-life (t1/2=4.2 h), plasma clearance (Cl=11.5 L/h/kg), and Cmax (1233 ng/mL) in rats. PD-1/PD-L1-IN-9 (25 mg/kg; a single p.o.) shows moderate oral bioavailability (F=22%), half-life (t1/2=6.4 h), and Cmax (192 ng/mL) in rats[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 90 mg/mL (258.3 mM), Sonication is recommended.
|
| Keywords | PD-L1 | PDL1 | PD-1/PD-L1-IN-9 | PD1/PDL1IN9 | PD-1/PD-L1 | PD1/PDL1 | PD-1 | PD1 | PD 1/PD L1 IN 9 |
| Inhibitors Related | LSD1-IN-24 | Sulfamethoxypyridazine | BMS-202 | PD-1-IN-22 | BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride | IMMH 010 maleate | Camrelizumab | LSD1-IN-27 | BMS-1 | Anti-Mouse PD-1 Antibody (RMP1-14) | Tomivosertib | PD-L1-IN-3 |
| Related Compound Libraries | Apoptosis Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Immuno-Oncology Compound Library | PPI Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Active Compound Library |
United States
